Tango Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Caleres Inc (CAL) reported Q2 earnings of $0.47 per share, beating estimates of $0.37, and raised FY26 EPS guidance. Shares rose 14.4% to $13.76. Other companies like Opus Genetics (IRD), Signet Jewelers (SIG), and Flotek Industries (FTK) also saw significant gains due to positive updates.
Crystal Adam (President, R&D) sold 27,000 shares of Tango Therapeutics, Inc. (TNGX) at $22.37 ($0.60M total) on 2026-09-01 under a Rule 10b5-1 trading plan.
Tangram Therapeutics announced its MASH treatment TGM-312 has progressed to patient cohorts in a Phase 1/2 trial. The company also appointed Dr. Sonya Montgomery as Chief Development Officer. TGM-312 targets liver inflammation and steatosis, with interim data expected in 2027. Dr. Montgomery brings 25 years of experience in clinical development.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning TNGX (Tango Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent TNGX coverage spans earnings, insider activity and corporate actions.
In the last 30 days, TNGX insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($604K). The most active reporter was Crystal Adam, President, R&D, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Price action likely due to sector momentum.
Insider sale may signal reduced confidence or portfolio rebalancing, potentially pressuring the stock short-term.
Advancement to MAD in MASH patients de‑risks the program and may boost share price ahead of data read‑out.
This is a new beneficial-ownership disclosure that can affect perceived shareholder base and potential governance influence, but it is not an operational catalyst.
The earnings miss and cost spike (G&A nearly doubled) are the immediate drivers of downside risk for TNGX, despite ongoing late-stage clinical progress.
AlphAI scores every news story that mentions TNGX with an AI model for sentiment and relevance, and aggregates insider trades from Tango Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Caleres Inc (CAL) reported Q2 earnings of $0.47 per share, beating estimates of $0.37, and raised FY26 EPS guidance. Shares rose 14.4% to $13.76. Other companies like Opus Genetics (IRD), Signet Jewelers (SIG), and Flotek Industries (FTK) also saw significant gains due to positive updates.
2 min readCrystal Adam (President, R&D) sold 27,000 shares of Tango Therapeutics, Inc. (TNGX) at $22.37 ($0.60M total) on 2026-09-01 under a Rule 10b5-1 trading plan.
1 min readTangram Therapeutics announced its MASH treatment TGM-312 has progressed to patient cohorts in a Phase 1/2 trial. The company also appointed Dr. Sonya Montgomery as Chief Development Officer. TGM-312 targets liver inflammation and steatosis, with interim data expected in 2027. Dr. Montgomery brings 25 years of experience in clinical development.
2 min readGoldman Sachs Group Inc. and Goldman Sachs & Co. LLC filed a Schedule 13G for Tango Therapeutics Inc. reporting a 6.0% beneficial stake in Tango common stock. The filing cites aggregate beneficial ownership of 9,742,402.80 shares, with shared voting power over 9,740,098.80 shares and shared dispositive power over 9,740,206.80 shares.
2 min readTango Therapeutics (TNGX) shares fell about 4% to $26.58 after Q2 2026 results missed expectations. Net loss widened to $0.37 per share versus $0.35 a year earlier, above the ~$0.32 consensus. The quarter again had zero revenue. General and administrative expenses nearly doubled to $22.6M from $11.3M, driven by personnel and share-based comp.
4 min readTango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 da
4 min readTango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Dr. Barbara Weber’s employment with Tango Therapeutics, Inc. (the “Company”) as its Executive Chair ended on August 3, 2026
2 min readCrystal Adam (President, R&D) sold 27,000 shares of Tango Therapeutics, Inc. (TNGX) at an average of $27.24 ($26.79–$27.35, $0.74M total) across 2 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
1 min readCanaccord Genuity raised its price target for Tango Therapeutics (NASDAQ:TNGX) to $46 from $42 and kept a Buy rating, citing a revised model that includes combined revenues from vopimetostat plus KRAS inhibitors in NSCLC. Jefferies upgraded TNGX to Buy and lifted its target to $60. Tango also signed an underwriting for about 18.2M shares plus pre-funded warrants, expecting ~$566.5M net proceeds for trials and R&D.
5 min readCrystal Adam (President, R&D) sold 27,000 shares of Tango Therapeutics, Inc. (TNGX) at an average of $29.59 ($29.34–$30.25, $0.80M total) across 2 trades on 2026-07-01 under a Rule 10b5-1 trading plan.
2 min read